Gastrointestinal symptoms in diabetes: Prevalence, assessment, pathogenesis, and management

Diabetes Care

Volumn 41, Issue 3, 2018, Pages 627-637

  Du, Yang T ^a,b   Rayner, Christopher K ^a,b   Jones, Karen L ^a,b   Talley, Nicholas J ^c,d,e   Horowitz, Michael ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF NEWCASTLE   (Australia)

^d MAYO CLINIC   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIEMETIC AGENT; AZITHROMYCIN; BOTULINUM TOXIN; CISAPRIDE; CLONIDINE; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOXYCYCLINE; ERYTHROMYCIN; LACTULOSE; LINACLOTIDE; METFORMIN; METOCLOPRAMIDE; METRONIDAZOLE; NORTRIPTYLINE; OCTANOIC ACID C 13; OPIATE; PANCREAS ENZYME; PLACEBO; PROKINETIC AGENT; QUINOLONE DERIVATIVE; RELAMORELIN; RIFAXIMIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; TECHNETIUM SULFUR COLLOID TC 99M; UNINDEXED DRUG; VELUSETRAG;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ARTICLE; BODY WEIGHT LOSS; COMORBIDITY; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DIET RESTRICTION; DISEASE ASSESSMENT; DRUG EFFICACY; DRUG RESPONSE; DYSPEPSIA; DYSPHAGIA; ELECTROSTIMULATION; ENDOSCOPY; ESOPHAGUS FUNCTION DISORDER; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH FIBER DIET; HUMAN; HYDROGEN BREATH TEST; INDIGESTION; INSULIN DEPENDENT DIABETES MELLITUS; IRRITABLE COLON; LOOSE FECES; LOW DRUG DOSE; MANOMETRY; MICROSCOPIC COLITIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATHOGENESIS; PERORAL ENDOSCOPIC MYOTOMY; PHYSICAL EXAMINATION; PREVALENCE; PYLOROPLASTY; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCINTIGRAPHY; SELF REPORT; SMALL INTESTINAL BACTERIAL OVERGROWTH; SMALL INTESTINE DISEASE; STOMACH DISEASE; STOMACH MOTILITY; STOMACH PARESIS; TREATMENT DURATION; TREATMENT OUTCOME; VALIDITY; VOMITING; DISEASE MANAGEMENT; GASTROINTESTINAL DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DIABETES MELLITUS; DISEASE MANAGEMENT; GASTROINTESTINAL DISEASES; HUMANS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85042604174     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-1536     Document Type: Article

References (92)

1. Ko GT, ChanWB, Chan JC, Tsang LW, Cockram CS.Gastrointestinal symptoms in Chinese patients with type 2 diabetes mellitus. Diabet Med 1999; 16:670-674.
2. Mjörnheim AC, Finizia C, Blohḿe G, Attvall S, Lundell L, Ruth M. Gastrointestinal symptoms in type 1 diabetic patients, as compared to a general population. A questionnaire-based study. Digestion 2003;68:102-108.
3. Abid S, Rizvi A, Jahan F, et al. Poor glycaemic control is the major factor associated with increased frequency of gastrointestinal symptoms in patientswithdiabetesmellitus. J Pak Med Assoc 2007;57:345-349.
4. de Kort S, Kruimel JW, Sels JP, Arts IC, Schaper NC, Masclee AA. Gastrointestinal symptoms in diabetes mellitus, and their relation to anxiety and depression. Diabetes Res Clin Pract 2012;96:248-255.
5. Ha JO, Lee TH, Lee CW, et al. Prevalence and risk factors of gastroesophageal reflux disease in patients with type 2 diabetes mellitus. Diabetes Metab J 2016;40:297-307.
6. Schvarcz E, Palmér M, Ingberg CM, Aman J, Berne C. Increased prevalence of upper gastrointestinal symptoms in long-Term type 1 diabetes mellitus. Diabet Med 1996;13:478-481.
7. Maleki D, Locke GR 3rd, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 2000;160:2808-2816.
8. Ricci JA, Siddique R, Stewart WF, Sandler RS, Sloan S, Farup CE. Upper gastrointestinal symptoms in a U.S. national sample of adults with diabetes. Scand J Gastroenterol 2000;35:152-159.
9. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: A population-based survey of 15, 000 adults. Arch Intern Med 2001;161:1989-1996.
10. Icks A, Haastert B, Rathmann W, Wareham N. Prevalence of gastrointestinal symptoms in patients with type 2 diabetes: A population-based study. Arch InternMed 2002;162:1067-1069; author reply 1069.
11. Quan C, Talley NJ, JonesMP, Spies J, Horowitz M. Gain and loss of gastrointestinal symptoms in diabetes mellitus: Associations with psychiatric disease, glycemic control, and autonomic neuropathy over 2 years of follow-up.Am J Gastroenterol 2008;103:2023-2030.
12. Hammer J, Howell S, Bytzer P, Horowitz M, Talley NJ. Symptomclustering in subjects with and without diabetes mellitus: A population-based study of 15, 000 Australian adults. Am J Gastroenterol 2003;98:391-398.
13. Mapel DW. Functional disorders of the gastrointestinal tract: cost effectiveness review. Best Pract Res Clin Gastroenterol 2013;27:913-931.
14. TalleyNJ, O'Keefe EA, Zinsmeister AR, Melton LJ 3rd. Prevalence of gastrointestinal symptoms in the elderly: A population-based study. Gastroenterology 1992;102:895-901.
15. Horowitz M, Harding PE, Maddox AF, et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989;32:151-159.
16. Ruth M, Mansson I, Sandberg N. The prevalence of symptoms suggestive of esophageal disorders. Scand J Gastroenterol 1991;26:73-81.
17. Talley NJ, Quan C, Jones MP, Horowitz M. Association of upper and lower gastrointestinal tract symptoms with body mass index in an Australian cohort. NeurogastroenterolMotil 2004;16: 413-419.
18. Corazziari E. Definition and epidemiology of functional gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2004;18:613-631.
19. Talley SJ, Bytzer P, Hammer J, Young L, Jones M, Horowitz M. Psychological distress is linked to gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol 2001;96:1033-1038.
20. Talley NJ, Young L, Bytzer P, et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am J Gastroenterol 2001;96:71-76.
21. Lacy BE, Crowell MD, Mathis C, Bauer D, Heinberg LJ. Gastroparesis: quality of life and health care utilization. J Clin Gastroenterol 2018; 52:20-24.
22. Florez H, Luo J, Castillo-Florez S, et al. Impact of met for min-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med 2010;122:112-120.
23. Bell RA, Jones-Vessey K, Summerson JH. Hospitalizations and outcomes for diabetic gastroparesis in North Carolina. South Med J 2002;95: 1297-1299.
24. Herman WH, Pop-Busui R, Braffett BH, et al.; DCCT/EDIC Research Group. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: Results fromthe Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med 2012;29:937-944.
25. Ghorbani S, Nejad A, Law D, Chua KS, Amichai MM, Pimentel M. Healthy control subjects arepoorly defined in case-control studies of irritable bowel syndrome. Ann Gastroenterol 2015;28:87-93.
26. Horowitz M, Aroda VR, Han J, Hardy E, Rayner CK. Upper and/or lower gastrointestinal adverse eventswith glucagon-like peptide-1 receptor agonists: incidence and consequences. Diabetes Obes Metab 2017;19:672-681.
27. Irvine EJ, Tack J, Crowell MD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2016;150:1469-1480.
28. Camilleri M, McCallum RW, Tack JF, Spence SC, Gottesdiener K, Fiedorek FT. Relamorelin in patients with diabetic gastroparesis: Efficacy and safety results from a phase 2B randomized, doubleblind, placebo-controlled, 12-week study (RM- 131-009). Gastroenterology 2017;152(Suppl. 1): S139-S140.
29. Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol 2008;4:1-32.
30. Quan C, Talley NJ, Cross S, et al. Development and validation of the Diabetes Bowel Symptom Questionnaire. Aliment Pharmacol Ther 2003;17: 1179-1187.
31. Ang D, Talley NJ, Simren M, Janssen P, Boeckxstaens G, Tack J. Review article: Endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmacol Ther 2011;33:634-649.
32. Talley NJ, Phillips SF, Melton J 3rd, Wiltgen C, Zinsmeister AR. A patient questionnaire to identify bowel disease. Ann InternMed 1989;111:671-674.
33. Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the Patient Assessment of Upper Gastrointestinal Symptom Severity Index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res 2004;13:1737-1749.
34. Revicki DA, Camilleri M, Kuo B, et al. Development and content validity of a gastroparesis cardinal symptomindex daily diary. Aliment Pharmacol Ther 2009;30:670-680.
35. Fehnel S, Nelson L, DiBennedetti D, Carson RT, Spence SC, Fiedorek FT. Development and psychometric evaluation of the Diabetic Gastroparesis Symptom Severity Diary. Gastroenterology 2017; 152(Suppl. 1):S517.
36. KumarA, Attaluri A, Hashmi S, Schulze KS, Rao SS. Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterol Motil 2008;20:635-642.
37. Brock C, Søfteland E, Gunterberg V, et al. Diabetic autonomic neuropathy affects symptom generation and brain-gut axis. Diabetes Care 2013;36:3698-3705.
38. Rayner CK, Verhagen MA, Hebbard GS, DiMatteo AC, Doran SM, Horowitz M. Proximal gastric compliance and perception of distension in type 1 diabetes mellitus: Effects of hyperglycemia. Am J Gastroenterol 2000;95:1175-1183.
39. Schvarcz E, Palmér M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997;113:60-66.
40. Horowitz M, Jones KL, Akkermans LMA, Samson M. Gastric function. In Gastrointestinal Function in Diabetes Mellitus. Horowitz M, Samsom M, Eds. Chichester, Wiley, 2004, p. 117-176.
41. Smout AJ. Oesophageal function. In Gastrointestinal Function in Diabetes Mellitus. Horowitz M, Samsom M, Eds. Chichester, Wiley, 2004, p. 97-116.
42. Iyer PG, Borah BJ, Heien HC, Das A, Cooper GS, Chak A. Association of Barrett's esophagus with type II diabetes mellitus: Results from a large population-based case-control study. Clin Gastroenterol Hepatol 2013;11:1108-1114.
43. Frøkjaer JB, Brock C, Brun J, et al. Esophageal distension parameters as potential biomarkers of impaired gastrointestinal function in diabetes patients. Neurogastroenterol Motil 2012;24: E1016-e544.
44. Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012;10:1360-1366.
45. Wilson JA, Vela MF. Newesophageal function testing (impedance, Bravo pH monitoring, and high-resolution manometry): clinical relevance. Curr Gastroenterol Rep 2008;10:222-230.
46. Koch KL. Diabetic gastropathy: gastric neuromuscular dysfunction in diabetesmellitus: A review of symptoms, pathophysiology, and treatment. Dig Dis Sci 1999;44:1061-1075.
47. Parkman HP, Hasler WL, Fisher RS; American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis.Gastroenterology 2004;127:1592-1622.
48. Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Melton LJ 3rd, Talley NJ. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol 2012;107:82-88.
49. Bharucha AE, Batey-Schaefer B, Cleary PA, et al.; Diabetes Control and Complications Trial- Epidemiology of Diabetes Interventions and Complications Research Group. Delayed gastric emptying is associated with early and long-Term hyperglycemia in type 1 diabetesmellitus. Gastroenterology 2015;149:330-339.
50. Dickman R, Wainstein J, Glezerman M, Niv Y, Boaz M. Gender aspects suggestive of gastroparesis in patients with diabetes mellitus: A crosssectional survey. BMC Gastroenterol 2014;14:34.
51. Chang J, Russo A, Bound M, Rayner CK, Jones KL, Horowitz M. A 25-year longitudinal evaluation of gastric emptying in diabetes. Diabetes Care 2012;35:2594-2596.
52. Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol 2011;9:1056-1064; quiz e133-e134.
53. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001;24: 1264-1269.
54. Bredenoord AJ, Chial HJ, Camilleri M, Mullan BP, Murray JA. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 2003;1:264-272.
55. Thazhath SS, Jones KL, Horowitz M, Rayner CK. Diabetic gastroparesis: Recent insights into pathophysiology and implications for management. Expert Rev Gastroenterol Hepatol 2013;7: 127-139.
56. Harberson J, Thomas RM, Harbison SP, Parkman HP. Gastric neuromuscular pathology in gastroparesis: Analysis of full-Thickness antral biopsies. Dig Dis Sci 2010;55:359-370.
57. Shin AS, Camilleri M. Diagnostic assessment of diabetic gastroparesis. Diabetes 2013;62:2667- 2673.
58. Sanaka M, Nakada K, Nosaka C, Kuyama Y. The Wagner-Nelson method makes the [13C]- breath test comparable to radioscintigraphy in measuring gastric emptying of a solid/liquid mixed meal in humans. Clin Exp Pharmacol Physiol 2007;34:641-644.
59. de Zwart IM, de Roos A. MRI for the evaluation of gastric physiology. Eur Radiol 2010;20: 2609-2616.
60. Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med 2007;356:820-829.
61. Tack J, Peeters T. What comes after macrolides and other motilin stimulants? Gut 2001;49: 317-318.
62. Deane AM, Fraser RJ, Chapman MJ. Prokinetic drugs for feed intolerance in critical illness: current and potential therapies. Crit Care Resusc 2009;11:132-143.
63. Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not men, with diabetes: Results of a phase 2B randomized study. Clin Gastroenterol Hepatol 2015;13:1256-1263.
64. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993;88: 203-207.
65. Lembo A, Camilleri M, McCallum R, et al. Relamorelin reduces vomiting frequency and severity and accelerates gastric emptying in adults with diabetic gastroparesis. Gastroenterology 2016; 151:87-96.
66. Carbone F, Rotondo A, Andrews CN, et al. 1077 A controlled cross-over trial shows benefit of prucalopride for symptomcontrol and gastric emptying enhancement in idiopathic gastroparesis. Gastroenterology 2016;150:S213-S214.
67. Goldberg M, Li YP, Johanson JF, et al. Clinical trial: The efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation -A 4-week, randomized, double-blind, placebo-controlled, doseresponse study. Aliment Pharmacol Ther 2010;32: 1102-1112.
68. Parkman HP, Van Natta ML, Abell TL, et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: TheNORIG randomized clinical trial. JAMA 2013;310:2640-2649.
69. Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L; American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013;108:18-37; quiz 38.
70. McCallum RW, Snape W, Brody F, Wo J, Parkman HP, Nowak T. Gastric electrical stimulation with Enterra therapy improves symptoms fromdiabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol 2010;8:947-954; quiz e116.
71. Ducrotté P, Coffin B, Mathieu N, et al. Gastric electrical stimulation (Ges) for Refractory vomiting: Results of a prospective multicenter doubleblinded randomized controlled cross-over trial. Gastroenterology 2017;152(Suppl. 1):S167.
72. Gaber AO, Oxley D, Karas J, et al. Changes in gastric emptying in recipients of successful combined pancreas-kidney transplants. Dig Dis 1991; 9:437-443.
73. U.S. Food and Drug Administration. Gastroparesis: Clinical Evaluation of Drugs for Treatment: Guidance for Industry. Food and Drug Administration Center for Drug Evaluation and Research. Silver Spring, Center for Drug Evaluation and Research, 2015.
74. Phillips LK, Rayner CK, Jones KL, Horowitz M. An update on autonomic neuropathy affecting the gastrointestinal tract. Curr Diab Rep 2006;6: 417-423.
75. Gould M, Sellin JH. Diabetic diarrhea. Curr Gastroenterol Rep 2009;11:354-359.
76. Chandrasekharan B, Anitha M, Blatt R, et al. Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress. Neurogastroenterol Motil 2011;23:131-138.
77. Russo A, Botten R, Kong MF, et al. Effects of acute hyperglycaemia on anorectal motor and sensory function in diabetes mellitus. Diabet Med 2004;21:176-182.
78. Elfström P, Sundström J, Ludvigsson JF. Systematic review with meta-Analysis: Associations between coeliac disease and type 1 diabetes. Aliment Pharmacol Ther 2014;40:1123-1132.
79. Bharucha AE, Dorn SD, Lembo A, Pressman A; American Gastroenterological Association. American Gastroenterological Associationmedical position statement on constipation. Gastroenterology 2013;144:211-217.
80. Pimentel M. Review of rifaximin as treatment for SIBO and IBS. ExpertOpin Investig Drugs 2009; 18:349-358.
81. Knop FK, Vilsbøll T, Larsen S, et al. Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab 2007;292:E324- E330.
82. Bharucha AE. Fecal incontinence. Gastroenterology 2003;124:1672-1685.
83. Lacy BE, Chey WD, Cash BD, Lembo AJ, Dove LS, Covington PS. Eluxadoline efficacy in IBS-D patientswho report prior loperamide use. AmJ Gastroenterol 2017;112:924-932.
84. Corbould A, Cam pbell J. Efficacy of octreotide but not long-Acting somatostatin analogue for severe refractory diabetic diarrhoea. Diabet Med 2009;26:828-829.
85. Fragkos KC, Źarate-Lopez N, Frangos CC. What about clonidine for diarrhoea? A systematic review and meta-Analysis of its effect in humans. Therap Adv Gastroenterol 2016;9:282-301.
86. Christie J, Shroff S, Shahnavaz N, et al. A randomized, double-blind, placebo-controlled trial to examine the effectiveness of lubiprostone on constipation symptoms and colon transit time in diabetic patients. Am J Gastroenterol 2017;112: 356-364.
87. Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab 2017;19:473-481.
88. Joshi SR, Standl E, Tong N, Shah P, Kalra S, Rathod R. Therapeutic potential of a-glucosidase inhibitors in type 2 diabetesmellitus: An evidencebased review. Expert Opin Pharmacother 2015; 16:1959-1981.
89. Kong MF, Stubbs TA, King P, et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998;41:577-583.
90. Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther 2009;2:203-214.
91. Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab 2017;19: 336-347.
92. Baraboi ED, St-Pierre DH, Shooner J, Timofeeva E, Richard D. Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4. Am J Physiol Regul Integr Comp Physiol 2011;301:R1011- R1024.